title: Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant.
abstract: BACKGROUND
  Specific anti-human leukocyte antigen antibodies (HLA) in the post-transplant period may be present with acute rejection episodes (ARE), and high soluble CD30 (sCD30) serum levels may be a risk factor for ARE and graft loss.
  
  
  METHODS
  HLA cross-matching, panel reactive antibodies (PRA), and sCD30 levels were determined prior to transplantation in 72 patients. Soluble CD30 levels and PRA were re-assessed at day 7, 14, 21, and 28, and monthly up to the sixth.
  
  
  RESULTS
  Twenty-four subjects had a positive PRA and 17 experienced ARE. Nine of 17 ARE subjects demonstrated positive PRA and 16 had HLA mismatches. Positive PRA was more frequent in ARE subjects (p = 0.03). Eight subjects with ARE had donor-specific antibodies (DSA) in serum samples pre-transplantation, two subjects developed DSA. Three subjects without ARE had positive PRA only in post-transplantation samples. Soluble CD30 levels were higher in pre-transplant samples and ARE subjects than non-ARE subjects (p = 0.03). Post-transplant sCD30 levels were elevated in subjects who experienced rejection and were significantly higher at seven d (p = 0.0004) and six months (p = 0.03).
  
  
  CONCLUSIONS
  Higher sCD30 levels following transplant were associated with ARE. Elevated sCD30 levels may represent a risk factor for acute rejection.
authors.affiliation: Histocompatibility and Cryopreservation Laboratory, Rio de Janeiro State University Nephrology Service, Bonsucesso General Hospital, Rio de Janeiro, RJ, Brazil.
authors.forename: Elizabeth M F L
authors.initials: EM
authors.lastname: Domingues
authors.forename: Teresa
authors.initials: T
authors.lastname: Matuck
authors.forename: Miguel L
authors.initials: ML
authors.lastname: Graciano
authors.forename: Edison
authors.initials: E
authors.lastname: Souza
authors.forename: Suzimar
authors.initials: S
authors.lastname: Rioja
authors.forename: Mônica C
authors.initials: MC
authors.lastname: Falci
authors.forename: Deise B
authors.initials: DB
authors.lastname: Monteiro de Carvalho
authors.forename: Luís Cristóvão
authors.initials: LC
authors.lastname: Porto
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D007518:Isoantibodies / Q000276:immunology*; D017730:Ki-1 Antigen / Q000097:blood*; D016030:Kidney Transplantation; D008297:Male; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D001323:Autoantibodies; D006680:HLA Antigens; D007518:Isoantibodies; D017730:Ki-1 Antigen